# A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma

> **NCT03579082** · PHASE4 · UNKNOWN · sponsor: **Mingzhi Zhang** · enrollment: 60 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT03579082
- **Lead sponsor:** Mingzhi Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-01
- **Primary completion:** 2019-06-01
- **Final completion:** 2019-12-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2018-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03579082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03579082, "A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03579082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*